<DOC>
	<DOCNO>NCT01662297</DOCNO>
	<brief_summary>This pilot comparative effectiveness study design determine whether trazodone effective quetiapine treatment insomnia veteran history addiction mental health issue . The study two concurrent phase ( part ) ; first acceptability determination phase , determine whether ( ) veteran already take quetiapine willing try alternative quetiapine sleep ; second , randomized trial phase test whether stay quetiapine advantage switch trazodone . The purpose first phase ) document proportion patient physician willing agree switch , b ) characterize sociodemographic clinical characteristic potentially eligible subject associate willingness switch quetiapine trazodone c ) record reason give patient prescribers ( ) willing accept switch quetiapine trazodone . It also function provide educational background patient reminder provider potential severe side-effects quetiapine , thus facilitate clinical inform consent clinical trial phase study . Completion first part study also serve screen component part II . Part II include , first , obtain write informed consent eligible subject , randomly assign continue quetiapine switch trazodone open-label `` real world '' fashion duration 4 week , follow another four week open , non-randomized follow- . The purpose second part study determine trazodone adequate substitute quetiapine , primarily term treat insomnia . The investigator hypothesize trazodone inferior quetiapine maintain good quality sleep measure sleep scale ( i.e. , score significantly worsen switch ) . This study open Veterans VA system . Eligible subject must history `` dual diagnosis '' ( i.e. , history addiction mental illness ) .</brief_summary>
	<brief_title>Comparison Quetiapine Trazodone Treatment Insomnia Dually Diagnosed Veterans</brief_title>
	<detailed_description>Part I study involve identification VA record subject eligible study base prescription quetiapine . Potentially eligible subject contact research team . Subjects answer brief questionnaire experience medication quetiapine use insomnia . If subject interested participate part II , clinical trial portion study , screen eligibility . Part II consist 4 week clinical trial subject randomize stay quetiapine switch trazodone , open-label . Subjects evaluate symptom sleep quality excessive daytime sleepiness . subject also assess change mood , alcohol/drug use . After initial 4 week treatment period , subject trazodone choose switch back quetiapine continue trazodone . Subjects also evaluate additional 4 week ( 8weeks start study ) outcome measure .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Trazodone</mesh_term>
	<criteria>Inclusion/Exclusion Criteria ( PHASE 1 ) : Identified VA prescribe provider take quetiapine primarily sedative/hypnotic agent form insomnia least 1 month Identified VA prescribe provider dual diagnosis ; lifetime history substance use disorder mental disorder Willing meet research assistant answer several question regard use experience quetiapine . Appear regularly medication would exclusion Part II ( see Part II exclusion criterion ) . Inclusion Criteria ( PHASE 2 ) : Willing provide write informed consent . Provider report primary use quetiapine insomnia least one month primary augmentation treatment mood , anxiety disorder , psychosis , mood stabilization . Have selfidentified provider confirm lifetime history mental health substance use disorder ( dual diagnosis ) . Currently take Quetiapine 300mg daily primary purpose treat insomnia , take least 1 month ( 30 day ) . Use acceptable method birth control female patient possibility become pregnant . The provider review patient identified chart , fill information patient drug , provider consent u approach client potentially switch ; investigator approach begin enrollment part II subject provider feel appropriate reason . Exclusion Criteria ( PHASE 2 ) : Physiologic substance dependence require detoxification past 30 day ( substance abuse exclusion ) . Concomitant administration : sedative hypnotic , benzodiazepine , prazosin , atypical antipsychotic , stimulant , ketoconazole inhibitor cytochrome P450 3A ( e.g. , itraconazole , fluconazole , erythromycin , protease inhibitor ) , phenytoin strong inducer cytochrome P450 enzyme . Intolerance hypersensitivity trazodone . Pregnant lactate woman woman plan become pregnant . Hepatic renal problem AST ALT ( &gt; 3 time upper limit normal ) ; Elevated bilirubin ( &gt; 1.2 ) , BUN ( &gt; 24 ) , creatinine ( &gt; 1.7 ) . Unstable , serious medical condition one require acute medical treatment , anticipation hospitalization extend care . Dementia , epilepsy , insulindependent diabetes , anticoagulation coumadin . Legal entanglement pending legal charge potential incarceration . Recent ( i.e. , past 3 month ) assault suicide gesture currently need acute intervention . Concurrent participation another clinical trial investigational drug last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Quetiapine</keyword>
	<keyword>Trazodone</keyword>
	<keyword>Insomnia</keyword>
	<keyword>Dual Diagnosis</keyword>
</DOC>